Hope With Answers: Specific Biomarkers

Currently, the biomarkers that have been identified for potential targeted therapy treatments for lung cancer are: EGFR, ALK, KRAS, MET, HER2, ROS1, BRAF, RET, NTRK1, PID3CA, MED1, VEGFR2, HER3, and IGF-1R.  Of those, so far only EGFR, ALK and ROS1 have treatments that have been approved by the FDA, but there are many more treatments that are in clinical trials. In this section of the Hope With Answers series, we will provide videos describing each biomarker and the most current information available regarding approved treatments.

Hope With Answers Video Series: Biomarker EGFR

Watch Dr. Natasha Leighl of Princess Margaret Hospital in Toronto discusses the EGFR mutation in lung cancer with patient and advocate Jill Feldman. Then watch Dr. Natasha Leighl discusses more details of the EGFR mutation in lung cancer with patient and advocate Ivy Elkins.

Get tested for all biomarkers at once?

New study shows it's cost effective.

Next-generation sequencing can identify hundreds from a small tissue sample at once.

Living with lung cancer

Dave Miller's story

Exercising after chemotherapy: When a weightlifter gets an unexpected diagnosis

Get informed.
Stay informed.

Join our community.

Sign up to get more resources on lung cancer risks, symptoms, and warning signs.